Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Medical Genetics

• Publication date

  2004-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1136/jmg.2003.012153PMID 14985375PMCID PMC1735695
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular diversity of structure and function of the voltage-gated Na+ channels.

  2002cited by this paper
• De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy.

  2001cited by this paper
• The primary erythermalgia-susceptibility gene is located on chromosome 2q31-32.

  2001cited by this paper
• Natural history of erythromelalgia: presentation and outcome in 168 patients.

  2000cited by this paper
• Channelopathies: ion channel defects linked to heritable clinical disorders

  2000cited by this paper
• Voltage-gated ion channels and hereditary disease.

  1999cited by this paper
• A Novel Tetrodotoxin-sensitive, Voltage-gated Sodium Channel Expressed in Rat and Human Dorsal Root Ganglia*

  1997cited by this paper
• Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons.

  1997cited by this paper
• Paramyotonia congenita: genotype to phenotype correlations in two families and report of a new mutation in the sodium channel gene.

  1996cited by this paper
• Structure and functional expression of a new member of the tetrodotoxin‐sensitive voltage‐activated sodium channel family from human neuroendocrine cells.

  1995cited by this paper
• ERYTHROMELALGIA AND ERYTHERMALGIA: DIAGNOSTIC DIFEERENTIATION

  1994cited by this paper
• Autosomal dominant erythromelalgia.

  1992cited by this paper
• Confirmation of linkage of hyperkalaemic periodic paralysis to chromosome 17.

  1991cited by this paper
• A Met-to-Val mutation in the skeletal muscle Na+ channel α-subunit in hyperkalaemic periodic paralysis

  1991cited by this paper
• Identification of a mutation in the gene causing hyperkalemic periodic paralysis.

  1991cited by this paper
• Three types of erythromelalgia.

  1990cited by this paper
• Idiopathic erythermalgia: a congenital disorder.

  1989cited by this paper
• Autonomic innervation of the skin in primary erythermalgia.

  1983cited by this paper
• Familial erythromelalgia.

  1982cited by this paper

• FK506 causes pain by upregulating NaV1.7 channels in the spinal dorsal root ganglia of NaV1.7–ChR2 mice

  2026influential citation
• Shaping the Action Potential in Dorsal Root and Trigeminal Ganglia Neurons: Relevance to Pain Mechanisms

  2026cites this paper
• Erythromelalgia as a paraneoplastic manifestation of colon cancer: A case report.

  2025cites this paper
• US drug agency approves potent painkiller — the first non-opioid in decades

  2025cites this paper
• Mimicking the Usual Suspects: Erythromelalgia in the Differential Diagnosis

  2025cites this paper
• Eritromelalgia como manifestación paraneoplásica de cáncer de colon. Reporte de caso

  2025cites this paper
• Surgical treatment of chronic ulcerative wounds of lower limbs in children with primary erythromelalgia: a case report and literature review

  2025cites this paper
• Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain

  2025influential citation
• Basic pain research ‘is not working’: Q&A with Steven Prescott and Stéphanie Ratté

  2025cites this paper
• Small-Fiber Neuropathy: An Etiology-Oriented Review

  2025cites this paper
• Canaux ioniques et douleur : la suzétrigine, une nouvelle molécule antalgique inhibitrice du canal sodique voltage-dépendant Nav-1.8

  2025cites this paper
• Nociceptor sodium channels shape subthreshold phase, upstroke, and shoulder of action potentials

  2025cites this paper
• Suzetrigine, a selective NaV1.8 inhibitor in acute and chronic pain: mechanistic insights, clinical outcomes, and future perspectives.

  2025cites this paper
• Towards development of Nav1.7 channel modulators for pain treatment: A comparison of mexiletine effect in two cell models by automated patch clamp.

  2025cites this paper
• Targeting Nav1.8 with the nonopioid antagonist suzetrigine in analgesia: cause for optimism?

  2025cites this paper
• Pediatric erythromelalgia from multidisciplinary perspectives: a scoping review

  2025cites this paper
• SCN9A should not be considered an epilepsy gene; Refuting a gene–disease association

  2025cites this paper
• Erythromelalgia: An unusual cutaneous manifestation of HSV infection? A case report

  2025cites this paper
• Spontaneous activity in pain patient stem cell-derived sensory neurons arises from one functional subclass.

  2025cites this paper
• Sodium Channel Inhibitors in Clinical Development for Pain Management: A Focused Review

  2025cites this paper
• Epigenetics of pain highways (Review)

  2025influential citation
• Voltage-gated sodium channels in excitable cells as drug targets

  2025influential citation
• Assessing NaV1.7 during tonic firing in pig C-nociceptors

  2025cites this paper
• Intrathecal administration of the Nav1.7 inhibitor PF-05089771 produces rapid and side-effect-free analgesia in mice.

  2025cites this paper
• Sensory neuron–expressed FGF13 controls nociceptive signaling in diabetic neuropathy models

  2025cites this paper
• Critical role of extracellular loops in differential modulations of TTX-sensitive and TTX-resistant Nav channels

  2025cites this paper
• Genetic Variants in the SCN9A Gene are Detected in a Minority of Erythromelalgia Patients

  2025cites this paper
• Small fiber neuropathy: expanding diagnosis with unsettled etiology

  2025cites this paper
• MODERN ASPECTS OF THE TREATMENT OF PAINFUL DIABETIC NEUROPATHY USING NEW GABAPENTINOID MIROGABALIN

  2025cites this paper
• Six at Sixty. ‘No gain, no pain’: medical genetics taking Nav1.7 from target to pharmacy

  2025cites this paper
• Refining the NaV1.7 pharmacophore of a class of venom‐derived peptide inhibitors via a combination of in silico screening and rational engineering

  2025influential citation
• Modification of Closed-State Inactivation in Voltage-Gated Sodium Channel Nav1.7 by Two Novel Arachnid Toxins

  2025cites this paper
• Mepyramine targets mutant Nav1.7 channels to relieve pain and erythema in primary erythromelalgia patients

  2025cites this paper
• Comprehensive Proteomic Profiling of Human Nav1.7-Interacting Proteins Reveals Conserved Regulatory Networks Involved in Nociceptive Signaling

  2025cites this paper
• From Traditional Medicine to Targeted Therapy: Structure-Activity Relationship-Guided Optimization of Scorpion Toxin DKK2 for Pain-Associated Sodium Channel Blockade.

  2025cites this paper
• Comparative Efficacy and Tolerability of Treatments for Erythromelalgia: A Systematic Review

  2025cites this paper
• Severe Erythromelalgia Pain Attack in a Young Lebanese Woman Leading to Hospitalization: A Case Report and Literature Review

  2025cites this paper
• Sensory neuron sodium channels as pain targets; from cocaine to Journavx (VX-548, suzetrigine).

  2025cites this paper
• Genetic and Clinical Insights into Inherited Erythromelalgia: A Comprehensive Review of Cases from China and Worldwide.

  2025cites this paper
• Primary Erythromelalgia: Historical Perspective and Current Update

  2025influential citation
• Voltage-gated sodium channels (NaV) in GtoPdb v.2025.3

  2025cites this paper
• Whole-genome resequencing revealed the Origin and Domestication of Chinese Domestic Rabbits

  2024cites this paper
• Similar excitability through different sodium channels and implications for the analgesic efficacy of selective drugs.

  2024influential citation
• Identification and In-Silico study of non-synonymous functional SNPs in the human SCN9A gene

  2024cites this paper
• Nav1.7 Modulator Bearing a 3-Hydroxyindole Backbone Holds the Potential to Reverse Neuropathic Pain.

  2024cites this paper
• Analgesic potential of voltage gated sodium channel modulators for the management of pain.

  2024cites this paper
• ST‐2560, a selective inhibitor of the NaV1.7 sodium channel, affects nocifensive and cardiovascular reflexes in non‐human primates

  2024influential citation
• IUPHAR Review: Navigating the role of preclinical models in pain research.

  2024cites this paper
• Role of NaV1.7 in postganglionic sympathetic nerve function in human and guinea‐pig arteries

  2024influential citation
• Molecular mechanisms of neuropathic pain.

  2024cites this paper
• Previously defined variants of uncertain significance may play an important role in epilepsy and interactions between certain variants may become pathogenic

  2024cites this paper
• Inhibition of TTX-S Na+ currents by a novel blocker QLS-278 for antinociception.

  2024cites this paper
• Eritromelalgia primaria

  2024cites this paper
• Genetic associations of neuropathic pain and sensory profile in a deeply phenotyped neuropathy cohort

  2024influential citation
• A versatile residue numbering scheme for Nav and Cav channels.

  2024cites this paper
• Potent and selective repression of SCN9A by engineered zinc finger repressors for the treatment of neuropathic pain

  2024cites this paper
• Congenital Insensitivity to Pain: A Case Study of a Rare Genetic Disorder

  2024cites this paper
• Human pain channelopathies.

  2024cites this paper
• JMG at 60

  2024cites this paper
• Spider and scorpion knottins targeting voltage-gated sodium ion channels in pain signaling.

  2024cites this paper
• Drug discovery targeting Nav1.8: Structural insights and therapeutic potential.

  2024cites this paper
• Discordance between preclinical and clinical testing of NaV1.7-selective inhibitors for pain

  2024cites this paper
• Shining a Light on Venom-Peptide Receptors: Venom Peptides as Targeted Agents for In Vivo Molecular Imaging

  2024cites this paper
• Differential expression of slow and fast-repriming tetrodotoxin-sensitive sodium currents in dorsal root ganglion neurons

  2024cites this paper
• The C-Terminal of NaV1.7 Is Ubiquitinated by NEDD4L

  2023cites this paper
• LmNaTx15, a novel scorpion toxin, enhances the activity of Nav channels and induces pain in mice.

  2023cites this paper
• Neanderthal introgression in SCN9A impacts mechanical pain sensitivity

  2023cites this paper
• A rare case of facial erythromelalgia: a promising way of treatment with combination of intense pulsed light and plasmapheresis

  2023cites this paper
• Exploring the Spectrum of RHOBTB2 Variants Associated with Developmental Encephalopathy 64: A Case Series and Literature Review

  2023cites this paper
• Primary Erythromelalgia : A Case Report Eritromelalgia primaria : a propósito de un caso

  2023influential citation
• Genetic, electrophysiological, and pathological studies on patients with SCN9A‐related pain disorders

  2023cites this paper
• Licochalcone Mediates the Pain Relief by Targeting the Voltage-Gated Sodium Channel

  2023cites this paper
• [[Translated article]]Primary Erythromelalgia: A Case Report.

  2023cites this paper
• Erythromelalgia. Part I: Pathogenesis, clinical features, evaluation, and complications.

  2023cites this paper
• Primary Erythromelalgia : A Case Report Eritromelalgia primaria : a propósito de un caso

  2023influential citation
• Clinical Challenges in Primary Erythromelalgia: a Real-Life Experience from a Single Center and a Diagnostic-Therapeutic Flow-Chart Proposal

  2023cites this paper
• Case report: Spinal cord stimulation in the treatment of pediatric erythromelalgia

  2023cites this paper
• Naphthylisoquinoline alkaloids, a new structural template inhibitor of Nav1.7 sodium channel

  2023cites this paper
• SCN9A rs6746030 Polymorphism and Pain Perception in Combat Athletes and Non-Athletes

  2023cites this paper
• Coexistence of erythromelalgia and Raynaud's phenomenon.

  2023cites this paper
• A Review of the Therapeutic Targeting of SCN9A and Nav1.7 for Pain Relief in Current Human Clinical Trials

  2023influential citation
• Voltage-gated sodium channels (NaV) in GtoPdb v.2023.1

  2023cites this paper
• Investigating genotype–phenotype relationship of extreme neuropathic pain disorders in a UK national cohort

  2023cites this paper
• NaV1.7 mRNA and protein expression in putative projection neurons of the human spinal dorsal horn

  2023cites this paper
• Nav1.7-P610T mutation in 2 siblings with persistent ocular pain after corneal axon transection: impaired slow-inactivation and hyperexcitable trigeminal neurons.

  2023cites this paper
• A severe case of primary erythromelalgia presenting as small fiber neuropathy with a novel SCN9A mutation

  2023cites this paper
• NAN-190, a 5-HT1A antagonist, alleviates inflammatory pain by targeting Nav1.7 sodium channels.

  2023cites this paper
• Neuropathic pain: Mechanisms and therapeutic strategies

  2023cites this paper
• Ectopic expression of Nav1.7 in spinal dorsal horn neurons induced by NGF contributes to neuropathic pain in a mouse spinal cord injury model

  2023cites this paper
• Structural mapping of Nav1.7 antagonists

  2023cites this paper
• Equivalent excitability through different sodium channels and implications for the analgesic efficacy of selective drugs

  2023influential citation
• Gene variant effects across sodium channelopathies predict function and guide precision therapy

  2022cites this paper
• Nav1.7 and Nav1.8 form supramolecular active clusters with TRKB in mouse and human DRG neurons during development of neuropathic pain

  2022cites this paper
• Structural basis for NaV1.7 inhibition by pore blockers.

  2022cites this paper
• Towards Zebrafish Models of CNS Channelopathies

  2022cites this paper
• Maximizing treatment efficacy through patient stratification in neuropathic pain trials

  2022cites this paper
• Inhibition of NaV1.7: the possibility of ideal analgesics.

  2022cites this paper
• Neuropathic pain

  2022cites this paper
• Familial Episodic Pain Syndromes

  2022cites this paper
• Medical care of rare and undiagnosed diseases: Prospects and challenges

  2022cites this paper